Fun for Avita
Wednesday, 16 July, 2008
Sales of Avita Medical's [AVH] respiratory products, including the Funhaler, increased 35 per cent last financial year, making up for the shelving of its CellSpray range of epithelial autograft products.
In a sales update released to the market, Avita said it had appointed pharmacy sales brokers Clear Sales as distributor of the Funhaler, an asthma device for children, for the Australian market earlier this year and is now actively searching for a US distributor following FDA approval last year.
Avita has also appointed a new senior sales executive, John Geisel, as senior vice-president of business development. He has over 35 years experience in medical sales and marketing.
Avita is the result of a merger between Clinical Cell Culture, which contributed the regenerative medicine product line, and Visiomed, an asthma device specialist with an eye on the ophthalmic market.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
